Cephalon Receives Approvable Letter for Sparlon

Drug Industry Daily
KEYWORDS FDA / Markets
A A

The FDA has issued Cephalon an approvable letter for its experimental attention-deficit/hyperactivity disorder (ADHD) drug Sparlon -- a development that financial analysts viewed as a positive.

To View This Article:

Login

Subscribe To Drug Industry Daily